{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:24:27Z","timestamp":1764833067645,"version":"3.46.0"},"reference-count":9,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>To explore the perioperative nursing protocols and complication management strategies for hepatocellular carcinoma (HCC) patients undergoing Yttrium-90 (Y-90) radioactive microsphere therapy.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was performed on clinical data from 15 HCC patients treated with Y-90 radioactive microspheres at Qilu Hospital of Shandong University between December 2024 and April 2025. A structured, multidisciplinary perioperative nursing protocol was implemented, consisting of: (1) Preoperative multidisciplinary evaluation including nutritional risk screening (NRS-2002), radiation dosimetry assessment, and vascular anatomy verification; (2) Intraoperative coordination with specific steps for patient positioning, vascular access establishment, radiation safety measures, and vital sign monitoring; (3) Postoperative dynamic monitoring of vital signs (every 2 h), puncture site condition, laboratory parameters (at 24 and 72 h), and symptom assessment using NRS for pain; (4) Tiered complication management system based on CTCAE v5.0 grading criteria. All 15 patients completed the treatment successfully. The postoperative complication rate was 73.3% (11\/15), with manifestations including abdominal pain (five cases), fatigue (three cases), leukopenia (three cases), thrombocytopenia (two cases), and low-grade fever (one case), all complications resolved with appropriate symptomatic management. No severe adverse events such as radiation-induced liver injury or significant myelosuppression occurred. Standardized perioperative nursing workflows, comprehensive radiation protection protocols, and an early-warning system for complications are essential to enhancing the safety of Y-90 microsphere therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1694152","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:32:32Z","timestamp":1764829952000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative nursing coordination and complication management in Yttrium-90 radioactive microsphere therapy for hepatocellular carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Xian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiangwei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3760\/cma.j.cn115610-20240228-00135","article-title":"Chinese expert consensus on conversion and perioperative treatment of primary liver cancer (2024 edition).","volume":"23","author":"Jia","year":"2024","journal-title":"Chin J Digest Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3760\/cma.j.cn115610-20230315-00108","article-title":"Chinese expert consensus on postoperative adjuvant therapy for liver cancer (2023 edition).","volume":"22","year":"2023","journal-title":"Chin J Digest Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2217\/fon-2020-1290","article-title":"Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.","volume":"17","author":"Liu","year":"2021","journal-title":"Future Oncol."},{"key":"B5","first-page":"2540","article-title":"Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.","volume":"13","author":"Lang","year":"2023","journal-title":"Am J Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.13929\/j.issn.1672-8475.2021.06.001","article-title":"Expert consensus on Yttrium-90 microsphere management.","volume":"18","author":"Song","year":"2021","journal-title":"Chin J Intervent Imaging Therapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12885-017-3921-1","article-title":"Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.","volume":"18","author":"Xing","year":"2018","journal-title":"BMC Cancer."},{"key":"B8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12025\/j.issn.1008-6358.2024.20240065","article-title":"Primary liver cancer diagnosis and treatment guidelines (2024 Edition).","volume":"31","year":"2024","journal-title":"Chin J Clin Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.3748\/wjg.v26.i30.4442","article-title":"Predictive model for acute abdominal pain after transarterial chemoembolization for liver cancer.","volume":"26","author":"Bian","year":"2020","journal-title":"World J Gastroenterol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1694152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:32:36Z","timestamp":1764829956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1694152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":9,"alternative-id":["10.3389\/fmed.2025.1694152"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1694152","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"article-number":"1694152"}}